Big Pharma trio backs cancer startup; AB jumps on ALS data; Shire founder oversees AIM listing

Nick Paul Taylor In this week's EuroBiotech Report, Metabomed celebrated adding Pfizer to a list of investors that already featured the VC units of Merck KGaA and Boehringer Ingelheim. ...

ACC latest: Lilly, Merck, Pfizer, Novartis and more unveil key data

Tracy Staton You missed the American College of Cardiology meeting. That's OK. The most newsworthy research coming out of the meeting is gathered right here, with almost every Big ...

FDA leaves biosim trial data off product labels in new guidance

Carly Helfand The FDA is out with new guidance for labeling biosimilar drugs–and it may not make some drugmakers happy. Regulators dismissed pharma's request that ...

New data boosts Novo against Sanofi in insulin-market fight

Carly Helfand Novo Nordisk has some new data in hand that could help a safety advantage make its way onto the label of new drug Tresiba–and win it points against heavyweight ...

Merus pulls forward target date for solid tumor data, reiterates intent to file IPO

Nick Paul Taylor Merus has shaved months off the date on which it expects to release data from a Phase I/II trial of its lead bispecific antibody in HER2-expressing solid tumors. The ...

Video: Experts predict the future of Big Data at #JPM16

Alok Saboo FierceBiotech News

Amgen’s PCSK9 outcomes trial to deliver data sooner than expected

Tracy Staton The wait for outcomes data on Amgen's PCSK9 drug Repatha just got shorter. As CardioBrief reports, top-line results of a study called Fourier will be available in the ...

Baxalta and Momenta target AbbVie’s blockbuster with positive biosim data

Damian Garde Partners Baxalta and Momenta Pharmaceuticals, among the many contenders looking to challenge the world's top-selling drug, posted positive data for their take on AbbVie's ...

Novartis keeps its CAR-T lead with positive Phase II data

Damian Garde Novartis, leading a pack of companies developing genetically engineered T cells to fight cancer, unveiled more promising data on its Phase II treatment as it wends toward ...

FDA rejects AstraZeneca’s diabetes combo and demands more data

Damian Garde The FDA wants to see more clinical trial data on AstraZeneca's new combination diabetes treatment, the company said, likely delaying a potential launch by more than ...

Boehringer touts Pradaxa antidote data as FDA decision nears

Carly Helfand LONDON–Boehringer Ingelheim's Pradaxa currently trails Johnson & Johnson and Bayer med Xarelto in the market for new-age anticoagulants, but the German drugmaker ...

UPDATED: Verastem shares crater on Twitter chatter around cancer data

John Carroll Shares of Verastem cratered Wednesday morning as the Twitter crowd passed around an abstract on the company's defactinib (VS-6063), highlighting an extremely poor response ...
Page 1 of 1212345...10...Last »
© 2017 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS